It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Multiple myeloma (MM) remains an incurable plasma cell (PC) malignancy. Although it is known that MM tumor cells display extensive intratumoral genetic heterogeneity, an integrated map of the tumor proteomic landscape has not been comprehensively evaluated. We evaluated 49 primary tumor samples from newly diagnosed or relapsed/refractory MM patients by mass cytometry (CyTOF) using 34 antibody targets to characterize the integrated landscape of single-cell cell surface and intracellular signaling proteins. We identified 13 phenotypic meta-clusters across all samples. The abundance of each phenotypic meta-cluster was compared to patient age, sex, treatment response, tumor genetic abnormalities and overall survival. Relative abundance of several of these phenotypic meta-clusters were associated with disease subtypes and clinical behavior. Increased abundance of phenotypic meta-cluster 1, characterized by elevated CD45 and reduced BCL-2 expression, was significantly associated with a favorable treatment response and improved overall survival independent of tumor genetic abnormalities or patient demographic variables. We validated this association using an unrelated gene expression dataset. This study represents the first, large-scale, single-cell protein atlas of primary MM tumors and demonstrates that subclonal protein profiling may be an important determinant of clinical behavior and outcome.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 Mayo Clinic, Division of Laboratory Genetics, Department of Laboratory Medicine and Pathology, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X); Mayo Clinic, Division of Hematopathology, Department of Laboratory Medicine and Pathology, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
2 Mayo Clinic, Division of Computational Biology, Department of Quantitative Health Sciences, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
3 Mayo Clinic, Division of Laboratory Genetics, Department of Laboratory Medicine and Pathology, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
4 Roswell Park Comprehensive Cancer Center, Department of Biostatistics and Bioinformatics, Buffalo, USA (GRID:grid.240614.5) (ISNI:0000 0001 2181 8635)
5 Mayo Clinic, Division of Hematology, Department of Internal Medicine, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
6 University of Minnesota, Division of Hematology, Oncology, and Transplantation, Department of Medicine and Masonic Cancer Center, Minneapolis, USA (GRID:grid.17635.36) (ISNI:0000000419368657)
7 University of Minnesota, Department of Laboratory Medicine and Pathology, Minneapolis, USA (GRID:grid.17635.36) (ISNI:0000000419368657)
8 Princess Margaret Cancer Centre, Toronto, Canada (GRID:grid.415224.4) (ISNI:0000 0001 2150 066X)
9 Mayo Clinic, Division of Hematology, Department of Internal Medicine, Scottsdale, USA (GRID:grid.417468.8) (ISNI:0000 0000 8875 6339)
10 Auburn University, Department of Drug Discovery and Development, Auburn, USA (GRID:grid.252546.2) (ISNI:0000 0001 2297 8753)
11 University of Minnesota, Department of Genetics, Cell Biology and Development, Minneapolis, USA (GRID:grid.17635.36) (ISNI:0000000419368657)